{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:47:47Z","timestamp":1785005267435,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Faperj","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Capes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.077","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:26:14Z","timestamp":1556583974000},"page":"3214-3220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture"],"prefix":"10.1016","volume":"37","author":[{"given":"T\u00e2nia P.","family":"Pato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta C.O.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo A.","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Caride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis F.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane P.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos S.","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5904-410X","authenticated-orcid":false,"given":"Leda R.","family":"Castilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.077_b0005","unstructured":"CDC. Yellow fever maps; 2018 [accessed on April 17, 2019]. <https:\/\/www.cdc.gov\/yellowfever\/maps\/index.html>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0010","doi-asserted-by":"crossref","first-page":"e1001638","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow Fever Expert Committee. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.04.077_b0015","unstructured":"WHO. Yellow fever vaccination booster not needed; 2013 [accessed on April 18, 2019]. <https:\/\/www.who.int\/mediacentre\/news\/releases\/2013\/yellow_fever_20130517\/en\/>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.077_b0025","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.1016\/j.vaccine.2010.10.015","article-title":"Is it time for a new yellow fever vaccine?","volume":"28","author":"Hayes","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.077_b0030","unstructured":"WHO. Eliminating Yellow Fever Epidemics (EYE) strategy: meeting demand for yellow fever vaccines; 2018 [accessed on April 18, 2019]. <https:\/\/www.who.int\/csr\/disease\/yellowfev\/meeting-demand-for-vaccines\/en\/>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0035","unstructured":"World Health Organization. Weekly epidemiological report, n\u00b0 14; 2016 [accessed on April 19, 2019]. <https:\/\/www.who.int\/wer\/2016\/wer9114.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0040","unstructured":"World Health Organization. Weekly epidemiological report, n\u00b0 32. 2017 [accessed on April 19, 2019]. <https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/258707\/WER9232.pdf?sequence=1>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0045","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMp1702172","article-title":"Yellow fever - once again on the radar screen in the Americas","volume":"376","author":"Paules","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2019.04.077_b0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1590\/0074-02760170134","article-title":"Genome analysis of yellow fever virus of brazil ongoing outbreak reveals polymorphisms","volume":"112","author":"Bonaldo","year":"2017","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2019.04.077_b0055","unstructured":"PAHO. Brazil launches world's largest campaign with fractional-dose yellow fever vaccine; 2018 [accessed on April 19, 2019]. <https:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=14065: brazil-launches-worlds-largest-campaign-with-fractional-dose-yellow-fever-vaccine>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0060","unstructured":"WHO. Yellow fever \u2013 Brazil; 2019 [accessed on April 18, 2019]. <https:\/\/www.who.int\/csr\/don\/11-february-2019-yellow-fever-brazil\/en\/>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0065","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.077_b0070","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/bit.25545","article-title":"Improved virus purification processes for vaccines and gene therapy","volume":"112","author":"Nestola","year":"2015","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2019.04.077_b0075","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.vaccine.2014.02.036","article-title":"Development of a membrane adsorber based capture step for the purification of yellow fever virus","volume":"32","author":"Pato","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.077_b0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.memsci.2007.04.048","article-title":"Direct capture of influenza A virus from cell culture supernatant with Sartobind anion-exchange membrane adsorbers","volume":"299","author":"Kalbfuss","year":"2007","journal-title":"J Membr Sci"},{"key":"10.1016\/j.vaccine.2019.04.077_b0085","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.memsci.2007.12.021","article-title":"Anion-exchange membrane chromatography for purification of rotavirus-like particles","volume":"311","author":"Vicente","year":"2008","journal-title":"J Membr Sci"},{"key":"10.1016\/j.vaccine.2019.04.077_b0090","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/btpr.25","article-title":"Towards purification of adenoviral vectors based on membrane technology","volume":"24","author":"Peixoto","year":"2008","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2019.04.077_b0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jviromet.2014.06.019","article-title":"A flow-through chromatography process for influenza A and B virus purification","volume":"207","author":"Weigel","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.04.077_b0100","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1016\/j.vaccine.2014.04.033","article-title":"Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purification","volume":"32","author":"Blom","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.077_b0105","unstructured":"GE HEALTHCARE. Data file 28-9983-07 AA \u2013 HiScreenTM CaptoTM Core 700; 2012 [accessed on April 19, 2019]. <https:\/\/www.gelifesciences.co.jp\/catalog\/pdf\/28998307.pdf>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0110","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.vaccine.2015.04.050","article-title":"Increasing Vero viable cell densities for Yellow Fever virus production in stirred-tank bioreactors using serum-free medium","volume":"33","author":"Mattos","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.077_b0115","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.1016\/j.vaccine.2009.06.023","article-title":"Production of yellow fever virus in microcarrier-based Vero cell cultures","volume":"27","author":"Souza","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.077_b0120","unstructured":"Pato TP. Desenvolvimento de um processo de purifica\u00e7\u00e3o do v\u00edrus da febre amarela produzida em c\u00e9lulas Vero. PhD thesis. Federal University of Rio de Janeiro, Biochemistry Program (PPGBq\/IQ), Brazil; 2014."},{"key":"10.1016\/j.vaccine.2019.04.077_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-1702(01)00273-8","article-title":"Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses","volume":"79","author":"Caufour","year":"2001","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2019.04.077_b0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/elps.1150080203","article-title":"Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels","volume":"8","author":"Blum","year":"1987","journal-title":"Electrophoresis"},{"key":"10.1016\/j.vaccine.2019.04.077_b0135","unstructured":"Chagas MG. Express\u00e3o da prote\u00edna de envelope e do v\u00edrus da febre amarela em Leishmania tarentolae. MSc Dissertation. MPTI\/Bio-Manguinhos\/FIOCRUZ, Brazil; 2013."},{"key":"10.1016\/j.vaccine.2019.04.077_b0140","unstructured":"PATH Vaccine and Pharmaceutical Technologies Group. Summary of stability data for investigational formulations of vaccines; 2012 [accessed on April 19, 2019]. <https:\/\/path.azureedge.net\/media\/documents\/TS_vaccine_stability_table_invest.pdf>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0145","unstructured":"WHO. Study Group on Cell Substrates for Production of biologicals; 2007 [accessed on April 19, 2019]. <http:\/\/www.who.int\/biologicals\/publications\/meetings\/areas\/vaccines\/cells\/Cells.FINAL.MtgRep.IK.26_Sep_07.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0150","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.vaccine.2015.03.077","article-title":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","volume":"33","author":"Pereira","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.077_b0155","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/bit.22304","article-title":"Host cell proteins in biologics development: identification, quantitation and risk assessment","volume":"103","author":"Wang","year":"2009","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2019.04.077_b0160","doi-asserted-by":"crossref","unstructured":"Ohtake S, Lechuga-Ballesteros D, Truong-Le V, Patzer E. Strategies for heat-stable vaccines. In: Wen EP, Ellis R, Pujar NS, editors. Vaccine development and manufacturing, 1st ed. [S.l.]: John Wiley & Sons, Inc.; 2015. p. 287\u2013318.","DOI":"10.1002\/9781118870914.ch10"},{"key":"10.1016\/j.vaccine.2019.04.077_b0165","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/gt.2009.33","article-title":"Purification of recombinant baculoviruses for gene therapy using membrane processes","volume":"16","author":"Vicente","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2019.04.077_b0170","unstructured":"FDA - Food and Drug Administration. Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications; 2010 [accessed on April 19, 2019]. <http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/vaccines\/ucm202439.pdf>."},{"key":"10.1016\/j.vaccine.2019.04.077_b0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.gt.3302624","article-title":"Downstream processing of viral vectors and vaccines","volume":"12","author":"Morenweiser","year":"2005","journal-title":"Gene Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:11Z","timestamp":1759401191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":35,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19305651"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}